Article Text

Download PDFPDF
Beyond scoring: a modern interpretation of disease progression in chronic liver disease
  1. Matteo Rosselli,
  2. Jane MacNaughtan,
  3. Rajiv Jalan,
  4. Massimo Pinzani
  1. Division of Medicine, University College London, UCL Institute for Liver and Digestive Health, Royal Free Hospital, London, UK
  1. Correspondence to Prof Massimo Pinzani, Division of Medicine, University College London, UCL Institute for Liver and Digestive Health, Royal Free Hospital Campus U3, Rowland Hill Street, London NW3 2PF, UK; m.pinzani{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


The progressive understanding of the natural history of chronic liver diseases (CLD) and the relative pathophysiological mechanisms have led to important improvements in the current management of these disorders. As for any cognitive course, this progress has been based on the establishment of identifiable endpoints. Along these lines, the introduction of staging systems based on the histopathological assessment of liver tissue fibrosis has allowed a reasonable understanding of what is defined as disease progression in CLD, and has facilitated the communication between clinicians and pathologists. However, there is increasing awareness that a simple semiquantitative fibrosis score does not adequately represent the complexity of the pathophysiological process leading to cirrhosis, and ultimately to life-threatening complications. Indeed, the categorisation in fibrosis stages is a clinical compromise that does not reflect the biological complexity of disease progression. This inadequacy becomes fully manifested in the stage defined ‘cirrhosis’, a phase of CLD often lasting several years, lacking appropriate clinical–pathological correlates.1 ,2

All these issues, and particularly those related to cirrhosis, are currently magnified by the increasing availability of potentially effective causative treatments (ie, antiviral agents for HCV and HBV CLD) with the emerging need of assessing/predicting disease stabilisation or even disease regression with relative accuracy. The aim of this article is to analyse this evolving area of hepatology, and focus on some relevant areas of research which will likely bring further advancement in the near future. In particular, the progression of CLD should be analysed according to aetiology-driven mechanisms, and by integrating the results of invasive and non-invasive methods with a clear mission towards the identification of predictive indexes guiding a more effective clinical management. Further complexity has been introduced by the recent description of the entity termed ‘acute on chronic liver failure’ (ACLF) which refers to a very rapid progression of …

View Full Text


  • Contributors The four authors contribute equally to the choice and development of the concepts expressed in the article.

  • Competing interests None.

  • Provenance and peer review Commissioned; externally peer reviewed.